Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taisho Pharmaceutical Estimates Higher Sales And Profits

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Taisho Pharmaceutical revised its forecast upward for the first two quarters of FY 2009 ending September. Company sales are estimated to increase to ¥128 billion, business profit to grow to ¥17 billion and a net profit increase to ¥10 billion, revised from ¥127 billion, ¥16 billion and ¥9.5 billion, respectively. According to the company, sales from new therapeutic drugs launched last year achieved better results than expected. Taisho kept the whole year forecast unchanged. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts